Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients
Por:
Hardy-Werbin, M, Quiroga, V, Cirauqui, B, Romeo, M, Felip, E, Teruel, I, Garcia, JJ, Erasun, C, Espana, S, Cucurull, M, Montprade, E, Pardo, JC, Carballo, D, Velarde, JM and Margeli, M
Publicada:
4 sep 2019
Ahead of Print:
4 sep 2019
Categoría:
Multidisciplinary
Resumen:
T-DM1 is an antibody drug conjugate that combines trastuzumab with emtansine via a stable thioether linker. In two phase III clinical trials, EMILIA and TH3RESA, T-DM1 was shown to be effective in HER2-positive metastatic breast cancer patients who had progressed to taxanes and trastuzumab. We have performed a real-world study to complement the findings of the clinical trials. From 2012 to 2016, 15 patients with HER2-positive breast cancer who had progressed to prior treatment received T-DM1 at our center. We have retrospectively analyzed outcomes in these patients and compared our findings with those of the two clinical trials. Progression-free survival (PFS) was 10 months compared with the 9.6 months of the EMILIA trial and the 6.2 months of the TH3RESA trial, overall survival was 34 months compared with the 29.9 months of the EMILIA trial and the 22.7 months of the TH3RESA trial. PFS was >= 12 months in five patients, three of whom attained a PFS of >= 23 months. Among five patients with metastases of the central nervous system, PFS was six months, OS was not reached, and the objective response rate was 80%. Our findings are in line with those of the EMILIA study and slightly superior to those of the TH3RESA study. In our series of patients, T-DM1 has demonstrated efficacy in the treatment of HER2-positive metastatic breast cancer. Our real-world data thus confirm and support the findings of the two major phase III trials and indicate the usefulness of T-DM1 in routine clinical practice.
Filiaciones:
Hardy-Werbin, M:
IMIM Hosp del Mar Med Res Inst, Canc Res Program, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
Garcia, JJ:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
Erasun, C:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
Montprade, E:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
Carballo, D:
Tecnol Monterrey, Escuela Med & Ciencias Salud, Mexico City, DF, Mexico
Velarde, JM:
Hosp Badalona Germans Trias & Pujol, Med Oncol Serv, Stat Dept, Inst Invest Ciencies Salut Germans Trias & Pujol, Badalona, Spain
:
Hosp Badalona Germans Trias & Pujol, Inst Catala dOncol, Med Oncol Serv, B ARGO Grp, Badalona, Spain
gold, Green Published
|